Brand Name of Dapagliflozin
Dapagliflozin is marketed under the brand names Farxiga in the United States and Forxiga in the European Union and other countries. 1, 2, 3, 4
Details About Dapagliflozin
Mechanism and Classification
- Dapagliflozin is a highly potent, reversible, and selective sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, leading to increased urinary glucose excretion and reduction in blood glucose levels 1
- It is classified as an SGLT2 inhibitor in diabetes management guidelines and is used for glycemic control in type 2 diabetes 5
Therapeutic Uses
- Approved for treatment of type 2 diabetes as monotherapy or add-on combination therapy with other glucose-lowering agents 1, 2
- Also approved for treatment of symptomatic heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status 5, 3
- Used in chronic kidney disease management to reduce disease progression and cardiovascular mortality 5, 6
Clinical Evidence
- In the DAPA-HF trial, dapagliflozin (Farxiga/Forxiga) demonstrated a 26% reduction in the risk of worsening heart failure or cardiovascular death compared to placebo 5
- In the DAPA-CKD study, dapagliflozin showed a 39% reduction in the risk of kidney disease progression, end-stage renal disease, and cardiovascular or renal death 5, 6
Dosing Considerations
- Standard dose is 10 mg orally once daily for both diabetes and heart failure indications 6
- Not recommended for glycemic control when eGFR <45 mL/min/1.73 m² due to reduced efficacy, though cardiovascular and renal benefits persist at lower eGFR levels 6
- Not recommended for initiation when eGFR <25 mL/min/1.73 m² 6
Common Side Effects
- Genital mycotic infections (more common in women) 5, 6, 2
- Urinary tract infections 5, 6
- Volume depletion 5, 6
- Low risk of hypoglycemia when used as monotherapy 1, 4
- Rare risk of diabetic ketoacidosis 6, 1